NLR与肿瘤同步放化疗预后的相关性研究

doi:10.11904/j.issn.1002-3070.2019.03.018

摘要/Abstract

摘要： 目前肿瘤治疗的临床方法主要是手术、放射治疗、化学药物治疗、中医学方法等综合治疗,然而有一些肿瘤由于起病隐匿,初次诊治已经进入中晚期,丧失手术机会,无法通过准确的手术分期评估预后。根治性同步放化疗可用于已无法手术治疗且放射治疗敏感的肿瘤。因此,探寻准确、经济的指标以评估放化疗预后已成为热点。中性粒细胞/淋巴细胞比值(Neutrophil to lymphocyte ratio,NLR)指治疗前外周血中中性粒细胞与淋巴细胞的比值,作为全身性的整体炎症反应指标,已有诸多研究证实其与肿瘤放化疗疗效的相关性,为评价肿瘤的预后提供了新的思路。本文对NLR与肿瘤同步放化疗预后相关性进行简要综述。

关键词: NLR, 同步放化疗, 预后

Abstract: By now,the clinical methods of cancer treatment are mainly surgery,radiotherapy,chemotherapy,and traditional Chinese medicine methods.However,some tumors are concealed due to onset,initial diagnosis and treatment,which have entered the middle and late stage,lost the operation opportunity and impossible to pass accurate surgical staging by assessment of prognosis.Radical concurrent chemoradiotherapy can be used for tumors that are inoperable and sensitive to radiation therapy.Therefore,it has become a hot spot to explore accurate and economic indicators to evaluate the prognosis of radiotherapy and chemotherapy.Neutrophil to lymphocyte ratio(NLR)refers to the ratio of neutrophils to lymphocytes in peripheral blood before treatment.As a general indicator of systemic inflammatory response,many studies have confirmed that the relationship between the efficacy of radiotherapy and chemotherapy for tumors provides a new way to evaluate the prognosis of tumors.This article briefly reviews the relationship between NLR and the prognosis of tumor-controlled radiotherapy and chemotherapy.

Key words: NLR, Concurrent chemoradiotherapy, Prognosis

中图分类号:

冯越,邢丽楠,王棹,张云艳. NLR与肿瘤同步放化疗预后的相关性研究[J]. 实用肿瘤学杂志, 2019, 33(3): 284-288.

FENG Yue,XING Linan,WANG Zhao,ZHANG Yunyan. Correlation between NLR and prognosis of concurrent chemoradiotherapy[J]. PRACTICAL ONCOLOGY JOURNAL, 2019, 33(3): 284-288.

参考文献

1 Kuang DM,Zhao Q,Wu Y,et al.Peritumoral neutrophils link inflammatory response to disease progression by fostering angiogenesis in hepatocellular carcinoma[J].J Hepatol,2011,54(5):948-955.
2 Mehrazin R,Uzzo RG,Kutikov A,et al.Lymphopenia is an independent predictor of inferior outcome in papillary renal cell carcinoma[J].Urol Oncol,2015,191(4):321-322.
3 Mantovani A,Allavena P,Sica A,et al.Cancer-related inflammation[J].Nature,2008,454(7203):436-444.
4 Mizunuma M,Yokoyama Y,Futagami M,et al.The pretreatment neutrophil-to-lymphocyte ratio predicts therapeutic response to radiation therapy and concurrent chemoradiation therapy in uterine cervical cancer[J].J Clin Oncol,2015,20(5):989-996.
5 Ding PR,An X,Zhang RX,et al.Elevated preoperative neutrophil to lymphocyte ratio predicts risk of recurrence following curative resection for stage IIA colon cancer[J].Int J Colorectal Dis,2010,25(12):1427-1433.
6 Zhang J,Huang SH,Li H,et al.Preoperative lymphocyte count is a favorable prognostic factor of disease-free survival in non-small-cell lung cancer[J].Med Oncol,2013,30(1):1-7.
7 Ardi VC,Kupriyanova TA,Deryugina EI,et al.Human neutrophils uniquely release TIMP-free MMP-9 to provide a potent catalytic stimulator of angiogenesis[J].Proc Natl Acad Sci U S A,2007,104(51):20262-20267.
8 Msph LAT,Bray F,Siegel RL,et al.Global cancer statistics,2012[J].CA Cancer J Clin,2015,65(2):87-108.
9 Mizunuma M,Yokoyama Y,Futagami M,et al.The pretreatment neutrophil-to-lymphocyte ratio predicts therapeutic response to radiation therapy and concurrent chemoradiation therapy in uterine cervical cancer[J].J Clin Oncol,2015,20(5):989-996.
10 Lee Y,Choi CH,Kim H,et al.Pretreatment neutrophil:lymphocyte ratio as a prognostic factor in cervical carcinoma[J].Anticancer Res,2012,32(4):1555.
11 Onal C,Guler OC,Yildirim BA.Prognostic use of pretreatment hematologic parameters in patients receiving definitive chemoradiotherapy for cervical cancer[J].Int J Gynecol Cancer,2016,26(6):1.
12 Wang YY,Bai ZL,He JL,et al.Prognostic value of neutrophil-related factors in locally advanced cervical squamous cell carcinoma patients treated with cisplatin-based concurrent chemoradiotherapy[J].Dis Markers,2016,40(12):1-9.
13 Najjar YG,Finke JH.Clinical perspectives on targeting of myeloid derived suppressor cells in the treatment of cancer[J].Front Oncol,2013,3:49.
14 Lee N,Harris J,Garden AS,et al.Intensity-modulated radiation therapy with or without chemotherapy for nasopharyngeal carcinoma:radiation therapy oncology group phase II trial 0225[J].J Clin Oncol,2009,27(22):3684.
15 Sun W,Zhang L,Luo M,et al.Pretreatment hematologic markers as prognostic factors in patients with nasopharyngeal carcinoma:neutrophil-lymphocyte ratio and platelet-lymphocyte ratio[J].Head Neck,2016,38(S1):1332-1340.
16 He JR,Shen G,Ren ZF,et al.Pretreatment levels of peripheral neutrophils and lymphocytes as independent prognostic factors in patients with nasopharyngeal carcinoma[J].Head Neck,2012,34(12):1769-1776.
17 Guo SP,Liu ZG,Tu ZW,et al.Haemoglobin,neutrophil to lymphocyte ratio and platelet count improve prognosis prediction of the TNM staging system in nasopharyngeal carcinoma:development and validation in 3237 patients from a single institution[J].J Clin Oncol,2013,25(11):639-646.
18 Li AC,Xiao WW,Wang L,et al.Risk factors and prediction-score model for distant metastasis in nasopharyngeal carcinoma treated with intensity-modulated radiotherapy[J].Tumour Biol,2015,36(11):8349-8357.
19 An X,Ding PR,Wang FH,et al.Elevated neutrophil to lymphocyte ratio predicts poor prognosis in nasopharyngeal carcinoma[J].Tumor Biol,2011,32(2):317-324.
20 李晓惠,徐冰清,高劲,等.中性粒细胞与淋巴细胞比值对鼻咽癌放射敏感性及预后影响的研究[J].中华放射肿瘤学杂志,2016,25(5):432-436.
21 Siegel RL,Miller KD,Fedewa SA,et al.Colorectal cancer statistics,2017[J].CA Cancer J Clin,2017,67(3):104-17.
22 Howington JA,Blum MG,Chang AC,et al.Treatment of stage I and II non-small cell lung cancer:Diagnosis and management of lung cancer,3rd ed:American college of chest physicians evidence-based clinical practice guidelines[J].Chest,2013,143(5):278-313.
23 Cannon NA,Meyer J,Iyengar P,et al.Neutrophil-lymphocyte and platelet-lymphocyte ratios as prognostic factors following stereotactic radiation therapy for early-stage non-small cell lung cancer[J].J Thorac Oncol,2015,10(2):280-285.
24 Shaverdian N,Veruttipong D,Wang J,et al.Pretreatment immune parameters predict for overall survival and toxicity in early-stage non-dmall-cell lung cancer patients treated with stereotactic body radiation therap[J].Clin Lung Cancer,2016,17(1):39-46.
25 Luo H,Ge H,Cui Y,et al.Systemic inflammation biomarkers predict survival in patients of early stage non-small cell lung cancer treated with stereotactic ablative radiotherapy-a single center experience[J].J Cancer,2018,9(1):182-188.
26 Unal D,Eroglu C,Kurtul N,et al.Are neutrophil/lymphocyte and platelet/lymphocyte rates in patients with non-small cell lung cancer associated with treatment response and prognosis?[J].Asian Pac J Cancer Prev,2013,14(9):5237-5242.
27 Ferlay J,Soerjomataram I,Dikshit R,et al.Cancer incidence and mortality worldwide:sources,methods and major patterns in GLOBOCAN 2012[J].Int J Cancer,2015,136:359-386.
28 Chandrasekara S,Davis S,Thomson P,et al.High neutrophil-to-lymphocyte ratio predicts poor prognosis in patients with squamous cell carcinoma of the head and neck treated with definitive chemoradiotherapy[J].Asia Pac J Clin Oncol,2018,14(5):442-447.
29 Moon H,Roh JL,Lee SW,et al.Prognostic value of nutritional and hematologic markers in head and neck squamous cell carcinoma treated by chemoradiotherapy[J].Radiother Oncol,2016,118(2):330-334.
30 Tempero MA,Malafa MP,Al-Hawary M,et al.Pancreatic adenocarcinoma,version 2.2017,NCCN clinical practice guidelines in oncology[J].Natl Compr Canc Netw,2017,15:1028-1061.
31 Konstantinidis IT,Warshaw AL,Allen JN,et al.Pancreatic ductal adenocarcinoma:is there a survival difference for R1 resections versus locally advanced unresectable tumors? What is a "true" R0 resection?[J].Ann Surg,2013,257(4):731-736.
32 Lee BM,Chung SY,Chang JS,et al.The neutrophil-lymphocyte ratio and platelet-lymphocyte ratio are prognostic factors in patients with locally advanced pancreatic cancer treated with chemoradiotherapy[J].Gut Liver,2018,12(3):342-352.
33 Alagappan M,Pollom EL,Von ER,et al.Albumin and neutrophil-lymphocyte ratio(NLR)predict survival in patients with pancreatic adenocarcinoma treated with SBRT[J].Am J Clin Oncol,2018,41(3):242-247.
34 Romano F,Uggeri F,Crippa S,et al.Immunodeficiency in different histotypes of radically operable gastrointestinal cancers[J],J Exp Clin Cancer Res,2004,23(2):195-200.
35 Jang R,Darling G,Wong RK.Multimodality approaches for the curative treatment of esophageal cancer[J].J Natl Compr Canc Netw,2015,13(2):229-238.
36 Chen MF,Chen PT,Lu MS,et al.Survival benefit of surgery to patients with esophageal squamous cell carcinoma[J].Sci Rep,2017,7:46139.
37 Chen MF,Chen PT,Kuan FC,et al.The predictive value of pretreatment neutrophil-to-lymphocyte ratio in esophageal squamous cell carcinoma[J].Ann Surg Oncol,2018,25(10):1-10.
38 Cox S,Hurt C,Grenader T,et al.The prognostic value of derived neutrophil to lymphocyte ratio in oesophageal cancer treated with definitive chemoradiotherapy[J].Radiother Oncol,2017,125(1):154-159.
39 Yoo EJ,Park JC,Kim EH,et al.Prognostic value of neutrophil-to-lymphocyte ratio in patients treated with concurrent chemoradiotherapy for locally advanced oesophageal cancer[J].Dig Liver Dis,2014,46(9):846-853.

[1]	王晓雅,肖斌,廖扬,唐荣芝,孙朝晖,李林海. CXCR家族蛋白在不同乳腺癌亚型中的表达及临床预后分析[J]. 实用肿瘤学杂志, 2019, 33(3): 206-210.
[2]	白晓斌, 霍龙伟, 谢万福, 徐高峰, 王茂德. Chk1在胶质母细胞瘤中的表达及其与肿瘤生物学行为和预后生存的关联性[J]. 实用肿瘤学杂志, 2019, 33(2): 122-127.
[3]	石小康, 丁佑铭, 汪斌, 余斌, 徐雨. UBE2T在原发性肝癌中的表达及临床意义[J]. 实用肿瘤学杂志, 2019, 33(2): 128-133.
[4]	卢姣云, 张清媛. 实验室标志物在弥漫大B细胞淋巴瘤预后中的研究进展[J]. 实用肿瘤学杂志, 2019, 33(2): 183-187.
[5]	赵凤娟, 王琪, 任贇虹, 韦珏伶, 黎乐群, 赵新华, 唐娟, 游雪梅. 肝癌伴抑郁患者血清CRP、hs-CRP水平变化及其对预后的影响[J]. 实用肿瘤学杂志, 2019, 33(1): 27-33.
[6]	张凤春, 江莺, 刘照南, 闫宁宁, 崔洪全, 徐迎春. 系统性炎症相关指标中性粒细胞/淋巴细胞比值及血小板/淋巴细胞比值在根治性切除术后的胃癌患者的预后意义[J]. 实用肿瘤学杂志, 2019, 33(1): 34-39.
[7]	马健力, 张明辉, 姬宏飞, 徐向英. PD-L1蛋白与CD8⁺TILs联合检测在可切除肺腺癌预后评估中的临床意义[J]. 实用肿瘤学杂志, 2019, 33(1): 40-46.
[8]	杨洪波, 石洁, 叶勇, 李文成, 邓兆平. COL5A2在膀胱癌组织中的表达及其与临床病理特征和预后的相关性分析[J]. 实用肿瘤学杂志, 2019, 33(1): 52-56.
[9]	王亚龙, 吕章艳, 张帆, 冯小双, 魏锣沛, 李鑫, 温艳, 高禹舜, 薛奇, 高树庚, 谭锋维. 人乳头状瘤病毒感染与肺癌预后相关性的Meta分析[J]. 实用肿瘤学杂志, 2018, 32(6): 520-526.
[10]	唐淑丽, 何匡邦, 张纯慧, 程佳楠, 张艳桥. 胃癌组织中miR-320a和CYLD的表达及与临床病理特征及预后的关系[J]. 实用肿瘤学杂志, 2018, 32(6): 538-544.
[11]	肖洪伟, 陈升, 王艳良, 苏学良. 距肛缘≤8 cm的T₁期直肠癌患者经肛门局部切除术的预后及影响因素分析[J]. 实用肿瘤学杂志, 2018, 32(6): 545-549.
[12]	王一然, 黄维, 尹蕾, 刘琳, 周晓平, 牛星鉴, 杨悦, 安巍巍, 姬宏飞. 中性粒细胞与淋巴细胞比值对宫颈癌患者同步放化疗疗效及预后判断的临床意义[J]. 实用肿瘤学杂志, 2018, 32(5): 404-409.
[13]	李美艳, 陈永学, 侯俊德. Leptin、VEGF及不同麻醉方式对子宫内膜癌患者预后生存的影响[J]. 实用肿瘤学杂志, 2018, 32(5): 426-431.
[14]	韩滕综述, 唐丽萍审校. PD-L1的表达与妇科恶性肿瘤预后关系的研究进展[J]. 实用肿瘤学杂志, 2018, 32(5): 468-470.
[15]	杜灵彬, 魏文强. 中国人群食管鳞癌生存分析研究新进展[J]. 实用肿瘤学杂志, 2018, 32(4): 344-348.